A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.

Clinical trial NCT06185543 · TERMINATED

Trial details

NCT number: NCT06185543
Sponsor: NeuroSense Therapeutics Ltd.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Alzheimer Disease

Start date: 2023-11-19
Primary completion: 2025-09-30
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.